NICE knocks back MSD’s Keytruda for lung cancer indication

pharmafile | February 28, 2017 | News story | Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda 

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for the treatment of untreated PD-L1-positive metastatic lung cancer.

NICE’s decision was spurred by the “immaturity of the data” provided by MSD, which made it impossible to accurately determine Keytruda’s overall survival benefits compared to current standard of care.

The institute ultimately determined that this lack of concrete supporting evidence meant that the cost-effectiveness estimate for the drug, which costs £2,630 for a 100mg vial, did not fall within its acceptable range, and as such will not be made available on the NHS.

The news comes as an unexpected misstep for the company after its immunotherapy drug scored a string of approval successes over the past few months, including in the indication of first-line treatment for metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have high PD-L1 expression in the EU.  

The decision is open for public consultation until 21 March.

Matt Fellows

Related Content

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …


Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based …

Latest content